$INCY Q3 '26 Earnings Results & Recap
• Reported GAAP EPS of -$3.60 down -259.29% YoY
• Reported revenue of $1.56B up 14.00% YoY
• Incyte raised full-year 2026 net sales guidance to $5.21B, Opzelura to $1.1B, and Hematology and Oncology to $890M, while reaffirming guidance for all other categories.